載入...
Methylxanthines: Potential Therapeutic Agents for Glioblastoma
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells...
Na minha lista:
| 發表在: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789489/ https://ncbi.nlm.nih.gov/pubmed/31500285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12030130 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|